Innovations in Blood-Based Biomarkers for Alzheimer’s Disease
Time: 9:30 am
day: Day Two
- Key features of assay development of plasma p-tau181 and p-tau231 on the Simoa platform: challenges but significant progress.
- Overview of plasma p-tau across the AD continuum: Do different epitopes provide different information at different times?
- Head-to-head comparisons of p-tau plasma biomarkers